News

#ATS2018 – CTEPH May Be a Genetic Disease, Study Suggests

Chronic thromboembolic pulmonary hypertension (CTEPH) may be an inherited genetic disease, a new study suggests. The results were recently presented at the American Thoracic Society (ATS) 2018 annual conference May 18-23 in San Diego. CTEPH, a rare form of pulmonary hypertension, is caused by blood clots that travel to the…

Acceleron Launches PULSAR Phase 2 Trial Testing Potential PAH Therapy Sotatercept

Acceleron Pharma, a biopharmaceutical company focused on rare diseases, has announced the start of the PULSAR Phase 2 clinical trial assessing the safety and effectiveness of sotatercept (ACE-011) in adults with pulmonary arterial hypertension (PAH). Sotatercept works by trapping members of the transforming growth factor-beta (TGF-beta) family, particularly those directly…